Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. Co. delivers its approved medicines, AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), to patients in the U.S. and Europe, and it is globally developing multiple programs for systemic mastocytosis lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Co. is developing a portfolio of investigational EGFR inhibitors such as BLU-945, BLU-701, BLU-525 and BLU-451, to address a range of common and uncommon epidermal growth factor receptor activating mutations, including exon 19 deletions, the L858R mutation and exon 20 insertions. We show 35 historical shares outstanding datapoints in our coverage of BPMC's shares outstanding history.
Understanding the changing numbers of BPMC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BPMC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BPMC by allowing them to research BPMC shares outstanding history
as well as any other stock in our coverage universe. |
Free BPMC Email Alerts:
Video: Shares Outstanding Importance
